The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Open accessAbstract
Purpose: The cardiac and antineoplastic effects of trastuzumab may be related to specific uptake of trastuzumab in myocardium and tumor tissue, respectively. We evaluated whether indium-111 (111 In) –labeled trastuzumab scintigraphy can predict cardiotoxicity and identify tumor lesions. In addition, we evaluated whether plasma markers for cardiac dysfunction can be used to predict cardiotoxicity. Patients and Methods: Patients with human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer underwent gamma camera imaging from 15 minutes to 7 days after injection of 150 MBq 111 In–diethylenetriamine penta-acetic acid anhydride (DTPA) –trastuzumab, after loading-dose trastuzumab, and after once-a-week trastuzumab doses for 11 weeks, and concomitant paclitaxel once every 3 weeks. Cardiac assessments were performed before treatment, and after four and six cycles. Plasma N-terminal probrain natriuretic peptide (NT-proBNP) and serum troponin I were measured with immunoassay. Results: Fifteen of the 17 patients were available for cardiac and tumor uptake analysis. On the first scan, myocardial 111 In-DTPA-trastuzumab uptake was observed in one patient with pre-existing cardiac arrhythmias, who did not develop heart failure during treatment. Severe cardiotoxicity occurred in three patients, without initial myocardial uptake, whereas one showed weak myocardial uptake after four cycles. The detection rate of single tumor lesions was 45%. New tumor lesions were discovered in 13 of 15 patients. Pretreatment plasma NT-proBNP levels were higher in patients with than without heart failure (mean, 534 [standard deviation, 236] v 105 [standard deviation, 79] ng/L; P = .009). Conclusion: Radiolabeled trastuzumab scintigraphy was not valuable in predicting trastuzumab-related cardiotoxicity in metastatic breast cancer patients, but can identify HER2-positive tumors. Measurement of plasma NT-proBNP is promising regarding prediction of trastuzumab-related cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
HER-2 gene amplification can be acquired as breast cancer progresses
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292
Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.15.1141 · Cited by 290
Meinardi, M. T., van Veldhuisen, D. J., Gietema, J. A., Dolsma, W. V., Boomsma, F., van den Berg, M. P., Volkers, C., Haaksma, J., de Vries, E. G. E., Sleijfer, D. T., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2746 · Cited by 207
Self-citationPreclinical characterisation of 111In‐DTPA‐trastuzumab
Lub‐de Hooge, M. N., Kosterink, J. G. W., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Suurmeijer, A. J. H., de Jong, S., Jager, P. L., & de Vries, E. G. E. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705915 · Cited by 176
Self-citationThe clinical evaluation of HER‐2 status: which test to use?
Bartlett, J. M. S., Mallon, E., & Cooke, T. (2003) · The Journal of Pathology · doi:10.1002/path.1354 · Cited by 161
Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas
Regitnig, P., Schippinger, W., Lindbauer, M., Samonigg, H., & Lax, S. (2004) · The Journal of Pathology · doi:10.1002/path.1592 · Cited by 129
Heß, G., Runkel, S., Zdunek, D., & Hitzler, W. E. (2005) · PubMed · Cited by 40
Fuchs, I. B., Landt, S., Bueler, H., Kuehl, U., Coupland, S. E., Kleine-Tebbe, A., Lichtenegger, W., & Schäller, G. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000003916.39959.73 · Cited by 37
Cited by
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
Self-citationImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Self-citationDevelopment and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., van Dongen, G. A. M. S., Bart, J., de Jong, J. R., de Vries, E. G. E., & Lub-de Hooge, M. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060392 · Cited by 334
Self-citation
Metadata
- Authors
- Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., & de Vries, E. G. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-05-20
- Volume
- 24
- Issue
- 15
- Pages
- 2276-2282
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160499123
- Cited by
- 310
- References
- 20
- FWCI
- 12.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.